Bristol-Myers Squibb Company
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher S. Boerner
- Full Time Employees
- 32,500
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Route 206 & Province Line Road Princeton NJ United States of America 08543
- IPO Date
- Jun 1, 1972
- CIK
- 0000014272
- Website
- bms.com
- Similar Companies
- Business
- Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company headquartered in Princeton, New Jersey with roots tracing to mergers of entities founded in 1858 and 1887, discovers, develops, manufactures, and commercializes innovative medicines for serious diseases including cancer, immunology, cardiovascular, hematology, and neuroscience disorders; its primary products include the anticoagulant Eliquis (apixaban), oncology therapies such as Opdivo (nivolumab), Yervoy, Krazati, and Revlimid (lenalidomide), cell therapies Abecma and Breyanzi, immunomodulators like Orencia and Pomalyst, legacy brands such as Abraxane, Camzyos for hypertrophic cardiomyopathy, Cobenfy in neuroscience, and others including Baraclude, IDHIFA, Inrebic, Nulojix, Opdivo Qvantig, Reblozyl, and Thalidomid; the company operates in more than 120 countries with a focus on oncology, hematology, immunology, cardiovascular, and fibrotic diseases targeting patients with high unmet needs. In recent developments, Bristol-Myers Squibb completes the acquisition of Orbital Therapeutics in 2025 to strengthen its cell therapy portfolio with RNA medicines reprogramming the immune system; it forms a joint venture with Bain Capital in July 2025 for innovative immunology therapies and enters a global strategic partnership with BioNTech in June 2025 to co-develop and co-commercialize next-generation bispecific antibody BNT327 for multiple solid tumors; earlier, the company acquires 2seventy bio in March 2025 for full control of Abecma amid competitive pressures, completes acquisitions of Karuna Therapeutics in March 2024 to bolster neuroscience, RayzeBio in February 2024 for actinium-based radiopharmaceuticals, and Mirati Therapeutics in January 2024 to diversify oncology, alongside a $380 million capacity agreement with Cellares in April 2024 for CAR T manufacturing.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Aureus Asset Management LLC Decreases Position in Bristol Myers Squibb Company $BMY
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
ABN Amro Investment Solutions Raises Stock Holdings in Bristol Myers Squibb Company $BMY
Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term
Bank of America Says the Fed Should Raise Rates Now: 4 Dividend Inflation-Resistant Stocks
Assetmark Inc. Sells 24,825 Shares of Bristol Myers Squibb Company $BMY
Andra AP fonden Sells 348,938 Shares of Bristol Myers Squibb Company $BMY
Bessemer Group Inc. Has $4.28 Million Stock Position in Bristol Myers Squibb Company $BMY
Bristol Myers Squibb Company $BMY Shares Sold by AlTi Global Inc.
Bristol Myers buys Nvidia's latest AI computing system for drug research
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
Dimensional Fund Advisors LP Has $1.14 Billion Stock Holdings in Bristol Myers Squibb Company $BMY
Allspring Global Investments Holdings LLC Boosts Stake in Bristol Myers Squibb Company $BMY
Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?